Blog
RSS FeedPosted by Michael Wonder on 08 Dec 2022
FDA authorises updated (bivalent) COVID-19 vaccines for children down to 6 months of age
8 December 2022 - Today, the US FDA amended the emergency use authorisations of the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 ...
Posted by Michael Wonder on 07 Dec 2022
US backs delay to decision on COVID patent waiver extension
6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...
Posted by Michael Wonder on 07 Dec 2022
Updated eligibility for COVID-19 oral treatment
7 December 2022 - COVID-19 treatments can be taken in your own home and can help reduce your symptoms. ...
Posted by Michael Wonder on 07 Dec 2022
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
7 December 2022 - Novavax today announced that Health Canada has approved a supplement to a new drug submission for Nuvaxovid ...
Posted by Michael Wonder on 07 Dec 2022
ETF concludes that bivalent original/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination
6 December 2022 - EMA’s Emergency Task Force considers that adapted mRNA bivalent vaccines targeting the original strain and Omicron ...
Posted by Michael Wonder on 06 Dec 2022
Molnupiravir ‘effective Covid-19 anti-viral’: acting CMO Michael Kidd
6 December 2022 - Acting chief medical officer Michael Kidd has contradicted the nation’s top advisers on Covid-19 treatments on ...
Posted by Michael Wonder on 06 Dec 2022
Pfizer and BioNTech submit application to US FDA for emergency use authorisation of Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine in children under 5 years
5 December 2022 - Pfizer andBioNTech today announced that the companies have submitted an application to the US FDA for ...
Posted by Michael Wonder on 04 Dec 2022
Anti-viral COVID-19 treatment now available in the Netherlands for 1,250 Euros
1 December 2022 - The anti-viral medication approved to treat COVID-19 is now available on the Dutch market, the Dutch Association ...
Posted by Michael Wonder on 04 Dec 2022
Anti-viral drug should not be first choice in treating COVID-19
3 December 2022 - The most widely prescribed anti-viral drug in Australia, molnupiravir, should no longer be routinely given for ...
Posted by Michael Wonder on 03 Dec 2022
COVID-19 vaccine safety report (1 December 2022)
1 December 2022 - To 27 November 2022, the TGA has received 709 reports which have been assessed as likely to ...
Posted by Michael Wonder on 28 Nov 2022
Joint statement: NICE and SMC/HIS collaboration
25 November 2022 - NICE and SMC/HIS collaboration on the health technology appraisal of tixagevimab–cilgavimab (Evusheld) for preventing COVID-19. ...
Posted by Michael Wonder on 24 Nov 2022
Outcome in relation to discussion of COVID-19 oral treatments – November 2022 PBAC meeting
24 November 2022 - A PBAC outcome in relation to discussion of COVID-19 oral treatments at the November 2022 meeting has ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises anti-viral treatment of COVID-19 to risk groups
21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be ...
Posted by Michael Wonder on 21 Nov 2022
Moderna applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine
18 November 2022 - Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222) ...
Posted by Michael Wonder on 19 Nov 2022
COVID-19 vaccine safety report (17 November 2022)
17 November 2022 - To 13 November 2022, the TGA has received 706 reports which have been assessed as likely to ...